SAN FRANCISCO, CA – NOVEMBER 11, 2011 – Researchers conducting the ADVISE clinical trial have concluded that a new measure of stenosis severity, instantaneous wave-free ratio (iFR), yielded similar results to traditional fractional flow reserve (FFR) without the use of adenosine to induce maximum hyperemia. Trial results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
FFR, while the leading invasive measure of stenosis severity, is only used in 6% or fewer of percutaneous coronary intervention (PCI) cases in the United States. One of the reasons for the low usage rate is the required use of the drug adenosine, which minimizes and stabilizes coronary resistance during the test, but is uncomfortable for patients, as well as being time-consuming and expensive.
In ADVISE (ADenosine Vasodilation Independent Stenosis Evaluation), 157 stenoses (131 patients) were recruited to this pilot, non–randomized, international, multi-center study. In their investigations, researchers developed a new pressure-based index that does not require adenosine.
Wave intensity analysis identified a period during the normal heart rhythm cycle where intracoronary resistance at rest is similar in variability and magnitude (CV: 0.08±0.06 and 284±147mmHg.s/m) to those during FFR (CV: 0.08±0.06 and 302±315mmHg.s/m, p=NS for both).
The resting ratio of the distal-to-proximal pressure during this period, iFR, correlated closely with FFR (r=0.9, p<0.001) with excellent diagnostic efficiency (receiver operating characteristic area under curve of 93%, at FFR<0.8), specificity, sensitivity, and negative and positive predictive values of 91%, 85%, 85% and 91%, respectively.
"The results of the ADVISE trial indicate that intra-coronary resistance is naturally constant and minimized during the wave-free period. The instantaneous wave-Free Ratio (iFR) calculated over this period produces a drug-free index of stenosis severity that is comparable to FFR," said principal investigator Justin Davies, MBBS, MRCP, PhD. Dr Davies is a clinical academic and interventional cardiologist at the National Heart and Lung Institute at Imperial College London.
"The clinical implications of the trial are that significant barriers to a physiological assessment of stenoses have been removed, and the new technique can potentially improve work-flow in the cath lab, leading to a better patient experience and increased adoption," said Dr. Davies.
This ADVISE trial was funded by the National Institute for Health Research, Biomedical Research Council and the Coronary Flow Trust and supported by Volcano Corporation. Dr. Davies holds licensed patents pertaining to this technology and has acted as a consultant for Volcano Corporation.
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies, drugs and therapies in interventional cardiovascular medicine.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.
For more information, visit www.crf.org.